Fruquintinib Combined With TAS-102 in Refractory Metastatic Colorectal Cancer

Fudan University logo

Fudan University

Status

Enrolling

Conditions

Refractory Colorectal Carcinoma
Metastatic Colorectal Cancer
Colorectal Cancer

Treatments

Drug: Fruquintinib Combined With TAS-102

Study type

Observational

Funder types

Other

Identifiers

NCT06221423
Fru plus TAS-102 in mCRC

Details and patient eligibility

About

Fruquintinib, as a standard treatment for refractory metastatic colorectal cancer (mCRC), has attracted increasing research efforts to explore its innovative strategies in combination with immunotherapy and chemotherapy because of its multi-target mechanism which enhances the sensitivity of the immune system and chemotherapy, aiming to further improve the survival benefits for mCRC patients. Trifluridine/tipiracil (TAS-102) is also a standard treatment for mCRC. This study aims to investigate the safety and effectiveness of the combined use of these two drugs in mCRC.

Enrollment

20 estimated patients

Sex

All

Ages

18 to 75 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Histology-confirmed metastatic CRC (mCRC)
  • Disease progression on standard therapy with at least two lines of chemotherapy, including fluorouracil, oxaliplatin, and irinotecan with or without biologics such as bevacizumab and cetuximab
  • Fruquintinib administered as salvage treatment
  • Age: 18-75 years old
  • Informed consent

Exclusion criteria

  • Liver or kidney dysfunction, or other conditions unsuitable for chemotherapy
  • Fruquintinib and/or TAS-102 administration as second-line treatment
  • Drug administration stopped after less than two cycles

Trial design

20 participants in 1 patient group

Fru plus TAS-102
Description:
mCRC patients receiveing Fruquintinib combined with TAS-102 in third- or late- line
Treatment:
Drug: Fruquintinib Combined With TAS-102

Trial contacts and locations

1

Loading...

Central trial contact

Donghao Xu

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems